KRAS and adenocarcinoma: The frequency of KRAS mutations in the EBUS-TBNA samples analysed in this study is in keeping with previous studies that reported KRAS mutation frequency of up to 22%, predominantly in adenocarcinomas [20] Importantly, KRAS mutations are associated with lack of response to EGFR inhibitor therapy in NSCLC [21].